A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
18 09 2023
18 09 2023
Historique:
received:
17
02
2023
accepted:
04
09
2023
medline:
20
9
2023
pubmed:
19
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 131 PDX models were established following heterotopical and/or orthotopical implantation in immunocompromised mice: 76 sarcomas, 25 other solid tumors, 12 central nervous system tumors, 15 acute leukemias, and 3 lymphomas. PDX establishment rate was 43%. Histology, whole exome and RNA sequencing revealed a high concordance with the primary patient's tumor profile, human leukocyte-antigen characteristics and specific metabolic pathway signatures. A detailed patient molecular characterization, including specific mutations prioritized in the clinical molecular tumor boards are provided. Ninety models were shared with the IMI2 ITCC Pediatric Preclinical Proof-of-concept Platform (IMI2 ITCC-P4) for further exploitation. This PDX biobank of unique recurrent childhood cancers provides an essential support for basic and translational research and treatments development in advanced pediatric malignancies.
Identifiants
pubmed: 37723198
doi: 10.1038/s42003-023-05320-0
pii: 10.1038/s42003-023-05320-0
pmc: PMC10507044
doi:
Banques de données
ClinicalTrials.gov
['NCT02613962']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
949Informations de copyright
© 2023. Springer Nature Limited.
Références
Leukemia. 2019 Oct;33(10):2429-2441
pubmed: 30914792
J Immunol. 2014 Nov 15;193(10):4790-802
pubmed: 25311805
N Engl J Med. 2015 Nov 12;373(20):1895-8
pubmed: 26559569
Nat Biotechnol. 2019 Aug;37(8):907-915
pubmed: 31375807
Nat Rev Clin Oncol. 2012 Apr 17;9(6):338-50
pubmed: 22508028
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Hum Mutat. 2017 Jul;38(7):788-797
pubmed: 28419628
Pediatr Blood Cancer. 2007 Dec;49(7):928-40
pubmed: 17066459
Cell Rep Methods. 2021 Jul 26;1(3):
pubmed: 34761247
Cancer Cell. 2019 Oct 14;36(4):385-401.e8
pubmed: 31564637
Nat Genet. 2017 Sep;49(9):1408-1413
pubmed: 28740262
Cell. 2016 Sep 22;167(1):260-274.e22
pubmed: 27641504
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Nat Genet. 2021 Jan;53(1):86-99
pubmed: 33414553
Cancer Med. 2018 Mar;7(3):665-676
pubmed: 29473324
Clin Cancer Res. 2020 Jul 1;26(13):3307-3318
pubmed: 32220889
Cancer Cell. 2021 Jun 14;39(6):827-844.e10
pubmed: 34129824
F1000Res. 2015 Jul 10;4:214
pubmed: 26925222
Cancer Discov. 2014 Sep;4(9):998-1013
pubmed: 25185190
Sci Rep. 2020 Mar 17;10(1):4897
pubmed: 32184413
Immunogenetics. 1999 Nov;50(3-4):201-12
pubmed: 10602880
Eur J Pharmacol. 2021 Apr 5;896:173921
pubmed: 33529725
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8059-8064
pubmed: 28674023
Clin Cancer Res. 2019 Dec 15;25(24):7294-7302
pubmed: 31506385
Methods Mol Biol. 2021;2226:223-242
pubmed: 33326106
Eur J Cancer. 2021 Nov;157:268-277
pubmed: 34543871
Genome Med. 2017 Sep 27;9(1):86
pubmed: 28954626
Nature. 2017 Sep 7;549(7670):96-100
pubmed: 28854174
Cancer Discov. 2022 May 2;12(5):1266-1281
pubmed: 35292802
J Immunol. 2004 Apr 1;172(7):4314-23
pubmed: 15034046
Cell Rep. 2019 Nov 5;29(6):1675-1689.e9
pubmed: 31693904
Front Oncol. 2023 Jun 12;13:1166063
pubmed: 37377921
Nat Commun. 2020 Sep 15;11(1):4629
pubmed: 32934208
Cancer. 2014 Aug 15;120(16):2497-506
pubmed: 24853691
Nat Rev Dis Primers. 2018 Jul 5;4(1):5
pubmed: 29977059
Clin Cancer Res. 2023 Apr 3;29(7):1317-1331
pubmed: 36602782
Cancer Res. 2021 Oct 1;81(19):4994-5006
pubmed: 34341072
Tumori. 2023 Jun;109(3):314-323
pubmed: 36114629
Cancer Discov. 2014 Feb;4(2):216-31
pubmed: 24436047
Cell Tissue Res. 2018 May;372(2):233-243
pubmed: 28924803
Clin Cancer Res. 2017 Oct 15;23(20):6101-6112
pubmed: 28733441
Cancer Res. 2022 Nov 15;82(22):4126-4138
pubmed: 36069866
Cells. 2019 Aug 13;8(8):
pubmed: 31412684
Nat Commun. 2021 Aug 24;12(1):5086
pubmed: 34429404
Nat Med. 2018 Nov;24(11):1752-1761
pubmed: 30349086
Cell Rep. 2020 Feb 11;30(6):1767-1779.e6
pubmed: 32049009
Int J Cancer. 2013 Oct 1;133(7):1547-56
pubmed: 23526331
J Clin Oncol. 2017 Jun 10;35(17):1879-1883
pubmed: 28426373
Acta Neuropathol. 2020 Aug;140(2):209-225
pubmed: 32519082
Cancer Immunol Immunother. 2005 Apr;54(4):400-6
pubmed: 15449039
BMC Immunol. 2008 Jan 22;9:1
pubmed: 18211710
Nat Commun. 2015 Jan 27;6:6125
pubmed: 25625758
J Clin Oncol. 2008 May 10;26(14):2384-9
pubmed: 18467730
J Clin Oncol. 2023 Jan 20;41(3):664-674
pubmed: 36375115
Cancer Res. 2020 Jun 1;80(11):2286-2297
pubmed: 32152150
Blood. 2020 Oct 1;136(14):1657-1669
pubmed: 32573700
Bioinformatics. 2017 Aug 01;33(15):2402-2404
pubmed: 28369222
Bioinformatics. 2014 Dec 1;30(23):3310-6
pubmed: 25143287
Neuro Oncol. 2017 Feb 1;19(2):153-161
pubmed: 27282398